These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2029695)

  • 41. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
    Chia LG; Cheng FC; Kuo JS
    J Neurol Sci; 1993 Jun; 116(2):125-34. PubMed ID: 8336158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension.
    Barbic F; Perego F; Canesi M; Gianni M; Biagiotti S; Costantino G; Pezzoli G; Porta A; Malliani A; Furlan R
    Hypertension; 2007 Jan; 49(1):120-6. PubMed ID: 17101845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twenty-four-hour ambulatory blood pressure and heart rate profiles in diagnosing orthostatic hypotension in Parkinson's disease and multiple system atrophy.
    Vichayanrat E; Low DA; Iodice V; Stuebner E; Hagen EM; Mathias CJ
    Eur J Neurol; 2017 Jan; 24(1):90-97. PubMed ID: 27718292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension.
    Kolloch R; Kobayashi K; DeQuattro V
    Hypertension; 1980; 2(4):390-4. PubMed ID: 7399622
    [No Abstract]   [Full Text] [Related]  

  • 48. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    Ramaker C; Hilten JJ
    Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment.
    Villeneuve A; Berlan M; Lafontan M; Caranobe C; Boneu B; Rascol A; Montastruc JL
    Eur J Clin Invest; 1985 Dec; 15(6):403-7. PubMed ID: 3007161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The drug treatment of Parkinson's disease.
    Morris JG
    Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
    Jellinger K
    J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment.
    Zhang L; Yuan Y; Tong Q; Jiang S; Xu Q; Ding J; Zhang L; Zhang R; Zhang K
    Int J Neurosci; 2016; 126(7):630-6. PubMed ID: 26004911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
    Chamontin B; Montastruc JL; Rascol A
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
    Przuntek H; Welzel D; Schwarzmann D; Letzel H; Kraus PH
    Eur Neurol; 1992; 32 Suppl 1():36-45. PubMed ID: 1425819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.
    Ogawa N
    Eur Neurol; 1994; 34 Suppl 3():20-8. PubMed ID: 7821332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.